Distribution, metabolism, and excretion of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 33, Issue 2, 2010, Pages 154-161

  Yancey, M F ^a   Merritt, D A ^a   White, J A ^a   Marsh, S A ^a   Locuson, C W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; NITRIC OXIDE; PALLADIA; PROTEIN TYROSINE KINASE INHIBITOR; TOCERANIB PHOSPHATE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE; BONE MARROW; COLON; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; FECES; FEMALE; HALF LIFE TIME; KIDNEY; LIVER; LIVER CELL; LUNG; LYMPH NODE; MALE; MASTOCYTOMA; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RADIOACTIVITY; SPECTROMETRY; SPLEEN; URINE;

ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; FEMALE; HEPATOCYTES; INDOLES; MALE; MICROSOMES; MOLECULAR STRUCTURE; PLASMA; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; PYRROLES; TISSUE DISTRIBUTION;

CANIS FAMILIARIS;

EID: 77949392424     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2009.01120.x     Document Type: Article

References (17)

1. Bethke, T.D., Böhmer, G.M., Hermann, R., Hauns, B., Fux, R., Mörike, K., David, M., Knoerzer, D., Wurst, W. & Gleiter, C.H. (2007) Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. Journal of Clinical Pharmacology, 47, 26-36.
2. Blaisdell, J., Goldstein, J.A. & Bai, S.A. (1998) Isolation of a New Canine cytrochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metabolism and Disposition, 26, 278-283.
3. Cashman, J.R. (1999) Handbook of Drug Metabolism, Ed. TF Woolf, Marcel Dekker, New York pp 477-505.
4. Cashman, J.R. (2005) Some distinctions between flavin-containing and cytrochrome P450 monooxygenases. Biochemical and Biophysical Research Communications, 338, 599-604.
5. Fisher, M.B., Yoon, K., Vaughn, M.L., Strelevitz, T.J. & Foti, R.S. (2002) Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo characterization and in vivo scaling of benzydamine clearance. Drug Metabolism and Disposition, 30, 1087-1093.
6. Hay Kraus, B.L., Greenblatt, D.J., Venkatakrishnan, K. & Court, M.H. (2000) Evidence for Propofol hydroxylation by cytochrome P4502B11 in Canine liver microsomes: breed and gender differences. Xenobiotica, 30, 575-588.
7. Kamimura, H. (2006) Genetic polymorphism of cytochrome P450s in beagles: possible influence of CYP1A2 deficiency on toxicological evaluations. Archives of Toxicology, 80, 732-738.
8. Lattard, V., Longin-Sauvageon, C., Lachuer, J., Delatour, P. & Benoit, E. (2002) Cloning, sequencing, and tissue-dependent expression of flavin-containing monooxygenase (FMO) 1 and FMO3 in the dog. Drug Metabolism and Disposition, 30, 119-128.
9. Lemos, C., Jansen, G. & Peters, G.J. (2008) Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. British Journal of Cancer, 98, 857-862.
10. Liao, A.T., Chien, M.B., Shenoy, N., Mendel, D.B., McMahon, G., Cherrington, J.M. & London, C.A. (2002) Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood, 100, 585-593.
11. London, C.A., Hannah, A.L., Zadovoskaya, R., Chien, M.B., Kollias-Baker, C., Rosenberg, M., Downing, S., Post, G., Boucher, J., Shenoy, M., Mendel, D.B., McMahon, G. & Cherrington, J.M. (2003) Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research, 9, 2755-2768.
12. London, C.A., Malpas, P.B., Wood-Follis, S.L., Boucher, J.F., Rusk, A.W., Rosenberg, M.P., Henry, C.J., Mitchener, K.L., Klein, M.K., Hintermeister, J.G., Bergman, P.J., Couto, G.C., Mauldin, G.N. & Michels, G.M. (2009) Multicenter, placebo-controlled, double-blind randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research, 15, 3856-3865.
13. Paulson, S.K., Engel, L., Reitz, B., Bolton, S., Burton, E.G., Maziasz, T.J., Yan, B. & Shoenhard, G.L. (1999) Evidence for polymorphism in the Canine metabolism of the Cyclooxygenase 2 inhibitor, Celecoxib. Drug Metabolism and Disposition, 27, 1133-1142.
14. Pryer, N.K., Lee, L.B., Zadovaskaya, R., Xiaoming, Y., Sukbuntherng, J., Cherrington, J.M. & London, C.A. (2003) Proof of target for SU11654: inhibition of KIT phosphorylation in Canine mast cell tumors. Clinical Cancer Research, 9, 5729-5734.
15. Roussel, F., Duignan, D.B., Lawton, M.P., Obach, R.S., Strick, C.A. & Tweedie, D.J. (1998) Expression and characterization of Canine cytrochrome P450 2D15. Archives of Biochemistry and Biophysics, 357, 27-36.
16. Stevens, J.C., Melton, R.J., Zaya, M.J. & Engel, L.C. (2003) Expression and characterization of functional dog flavin-containing monooxygenase 1. Molecular Pharmacology, 63, 271-275.
17. Yancey, M.F., Merritt, D.A., Lesman, S.P., Boucher, J.F. & Michels, G.M. (2009) Pharmacokinetic properties of toceranib phosphate (PalladiaTM, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. Journal of Veterinary Pharmacology and Therapeutics. (in press).